Business
Company Update & Change of Adviser
Company Update & Change of Adviser.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9755H ValiRx PLC 06 August 2019 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nCompany Update and Change of Adviser\n \nLondon, UK., 06 August 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that, further to the announcements released by the Company on 2 May 2019 and 25 June 2019, the discussions for the intention to form the joint venture with Alpha Blue Ocean have not progressed and will be considered along with other opportunities. \n \nThe Company also announces that further to the notification of 25 June 2019, the Company is still waiting on receipt of the R&D tax credit of £400,000 from HMRC. The Company expects to receive this amount shortly. As a result, the Company continues to carefully manage its working capital position. A further notification will be made in due course.\n \nThe Company notes that SVS Securities plc (\"SVS\") has been placed into Special Administration. As a consequence, Novum Securities Limited is now the Company's sole broker with immediate effect.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray / Jo Turner / Ludovico Lazzaretti\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\n\n\n\n\n\n\n\n\nNovum Securities Limited (Broker)\nColin Rowbury\n\n\nTel: +44 (0) 20 7399 9400\n\n\n\n \nNotes for Editors \n \nAbout ValiRx\nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aimi...